Quarterly ResultJul 28, 2026, 07:21 AM
Repligen Q2 Revenue $204M, Adj. EPS $0.54; Raises FY26 Guidance
AI Summary
Repligen Corporation reported strong financial results for the second quarter ended June 30, 2026, with revenue reaching $204 million, marking a 12% reported and 13% organic increase year-over-year. Adjusted EPS rose significantly to $0.54 from $0.37 in the prior year period. The company also raised its full-year 2026 organic revenue growth guidance to 10.5%-13.5% and adjusted EPS guidance to $2.03-$2.09, reflecting confidence in its performance. Additionally, Repligen announced a definitive agreement to acquire BioLife Solutions, aiming to strengthen its position in cell therapy.
Key Highlights
- Q2 2026 reported revenue was $204 million, a 12% year-over-year increase.
- Q2 2026 organic revenue growth was 13% year-over-year.
- Q2 2026 adjusted EPS was $0.54, compared to $0.37 in Q2 2025.
- Q2 2026 adjusted operating income was $34 million, a 55% increase year-over-year.
- Full-year 2026 organic revenue growth guidance raised to 10.5%-13.5%.
- Full-year 2026 adjusted EPS guidance raised to $2.03-$2.09.
- Cash, cash equivalents and marketable securities were $810 million at June 30, 2026.
- Announced definitive agreement to acquire BioLife Solutions.
Price Impact
More from RGEN